Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
My Bing
Health
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Trending on Bing
Willing to run for president
Innocent after 43-yrs of jail
'I learned nothing'
'Territorial integrity' of UKR
Poll: Black voters' support
Honeybees detect cancer?
LA wildfire: 1,200 evacuated
Returns key to NYC
Murder suspect arrested
Hajj pilgrims die from heat
Warns on terrorist threat
Speaks w/ voters in Detroit
Splash pad shooter identified
Faces new criminal charge
GA inmate kills worker, self
Victim of 1983 murder ID'd
2024 US Open
Lawmakers pass AZ budget
Mark 27 years of marriage
Juneteenth event shooting
Heat wave on Father’s Day
Breaks attendance record
Khanna won't attend address
IDF to begin 'tactical pause'
Biden slams Supreme Court
Honduras plans 'megaprison'
‘Confident' of UFC return
Missing American found dead
RU kills 6 hostage takers
On predicting Dec rate cut
Challenges Biden to a test
WWII plane remains found
On 2020 election results
Halts AI model launch in EU
Renowned NYC chef dies
Oilers rout Panthers
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults
New: The FDA has expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
FDA Expands Use of RSV Vaccine to Include More Adults
The FDA expanded the approval of GSK's respiratory syncytial virus (RSV) vaccine (Arexvy) to include adults ages 50 to 59 at risk of RSV-related lower respiratory tract disease (LRTD) due to underlying conditions, the company announced on Friday.
FDA approves RSV vaccine for adults 50 to 59
The Arexvy respiratory syncytial virus (RSV) vaccine, which is already approved for adults 60 and up, is now indicated for use in people ages 50 to 59 years old thanks to recent Food and Drug Administration approval.
US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label
The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
Adults 60+ Will Have 3 RSV Vaccines to Choose From This Year
Moderna's RSV vaccine, the first RSV vaccine to use mRNA, earned FDA approval for adults 60 and up. Here's what you need to know.
FDA Approves Moderna’s RSV Vaccine For Older Adults
CIDRAP reports on the approval of Moderna's mRNA vaccine, called mRESVIA, which is expected to be available during the 2024-25 respiratory virus season. Other news is on a rise in whooping cough cases and the latest developments on the bird flu virus.
GSK's Arexvy RSV Vaccine Gets FDA's Approval For Adults Aged 50-59
GSK plc (GSK, GSK.L) announced Monday that the US Food and Drug Administration has approved Arexvy, Respiratory Syncytial Virus or
FDA approves Moderna's RSV vaccine, its second marketed product
The Food and Drug Administration approved Moderna's RSV vaccine to prevent lower respiratory tract disease in adults aged 60 or older
FDA Approves New RSV Vaccine for Individuals Aged 50-59
On Friday, the Food and Drug Administration (FDA) approved Arexvy, a vaccine designed to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), for
FDA Gives Nod to RSV Vaccine for People in Their 50s
The vaccine is meant for those people with conditions such as COPD, asthma or diabetes that raise health risks if they contract RSV
Des Moines Register
16d
FDA approves Moderna's RSV vaccine, its second marketed product
The U.S. Food and
Drug
Administration has approved Moderna's
respiratory syncytial virus
vaccine
, the company announced on Friday, giving it a shot at much-needed new revenue from a second ...
The American Journal of Managed Care
5d
FDA Approves Expanded Age Indication for RSV Vaccine Arexvy
The first
respiratory syncytial virus
(
RSV
)
vaccine
has been approved for adults aged 50 to 59 years who are at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback